ADVA launches auto-tunable transceiver to help operators easily scale access networks to 25G
15.9.2022 10:00:00 EEST | Business Wire | Press release
ADVA (FSE: ADV) today launched its AccessWave25™, empowering network operators to easily migrate their 10Gbit/s access infrastructure to 25Gbit/s connectivity without a significant increase in footprint or major changes to the existing optical layer. The pluggable device answers the urgent need for higher bandwidth services in mobile X-Haul, cable access and wholesale networks. Operators can now slot the AccessWave25™ into any standard-based SFP28 port for an instant capacity upgrade without replacing existing demarcation or aggregation devices. Using patent-pending distance optimization technology, the device also extends 25Gbit/s DWDM reach to 40km, and its G.metro auto-tuning technology reduces provisioning efforts and simplifies operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220914005787/en/
ADVA’s AccessWave25™ offers an easy route to 25G DWDM connectivity in access networks without any major upgrades. (Photo: Business Wire)
“Our AccessWave25™ is the key to unlocking more bandwidth at the edge. Now network operators have an easy, low-cost way to address soaring bandwidth consumption that doesn’t require extra real estate or cause major disruption to services. And as well as boosting capacity, the AccessWave25™ offers a substantial increase in reach. While today’s solutions can’t go beyond 15km, our new pluggable device uses PAM4 modulation and direct-detection technology to support data transport up to 40km,” said Christoph Glingener, CEO of ADVA. “Simple to deploy and ideally suited for outdoor use, our AccessWave25™ device will be the foundation for the next generation of optical access networks.”
ADVA’s AccessWave25™ plug enables the seamless upgrade of fiber-based access networks. Host-agnostic and with a standardized SFP28 form factor, it empowers operators to instantly connect switches, routers and many other devices to DWDM open line systems. With full C-band tunable interfaces and G.metro self-tuning capabilities, the device reduces set-up time, minimizes human error and delivers operational cost savings. Network operators can also use the G.metro communication channel to remotely monitor the status and health of plugs for easy troubleshooting of any issues. Using less than 3 watts and with an I-temp hardened design, the AccessWave25™ is perfect for deployment in a wide range of outdoor settings.
“The latest addition to our pluggable technology portfolio answers the most urgent needs of our customers in a wide range of industries. From the core to the metro to access networks, our product range offers a plug for almost every situation,” commented Saeid Aramideh, VP of business development at Optical Engines, ADVA. “OurAccessWave25™ is a vital addition to our AccessWave™ family of pluggable devices and features our latest G.metro technology. Either with a third-party OLS or with our turnkey FSP 3000 solution for passive optical access networks, our pluggable technology provides the tools for tackling relentless growth in data consumption as well as the ever-changing demands of optical access networks.”
Further details on the ADVA AccessWave25™ are available in these slides: https://adva.li/accesswave25-slides.
A supporting product video is also available here: https://youtu.be/bcV06nMJ3_c.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005787/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 09:50:00 EET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU ® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 09:30:00 EET | Press release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The application is based on data from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. In the trial, ENHERTU demo
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 09:00:00 EET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term commitment to the Italian market, where the company has deep industrial roots
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 03:18:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Perpetual Atomics Ltd, QSA Europe, QSA Global and Reef Origin to Collaborate on Building Radioisotope Power Systems in Europe18.2.2026 17:44:00 EET | Press release
Perpetual Atomics Ltd, QSA Europe (a trading name of Loma Systems s.r.o.), QSA Global, Inc., and Reef Origin signed an MOU in Prague to collaborate on the industrialized production of radioisotope power systems in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218036211/en/ Teams from Perpetual Atomics & QSA Global (USA and Czechia) at the facilities in Czechia This MOU builds on the existing collaboration between QSA Global, Inc. and Perpetual Atomics Ltd by expanding and strengthening the capacity and capability to produce radioisotope power systems in Europe. The key partnership with QSA Europe provides access to existing facilities, capabilities, knowledge, and know-how for the storage, handling, and distribution of commercial radioisotope systems for terrestrial applications. This capability is directly transferable to radioisotope power technologies for space. Radioisotope and nuclear power technologies are
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom